Biology Reference
In-Depth Information
143. Rye PT, Delaney JC, Netirojjanakul C, Sun DX, Liu JZ,
Essigmann JM. Mismatch repair proteins collaborate with meth-
yltransferases in the repair of O(6)-methylguanine.
DNA Repair
(Amst)
2008;7:170
164. Carson DA, Kaye J, Wasson DB. Differences in deoxyadenosine
metabolism in human and mouse lymphocytes.
J Immunol
1980;
124:8
12.
165. Avramis VI, Plunkett W. Metabolism and therapeutic efficacy of
9-beta-D-arabinofuranosyl-2-fluoroadenine
e
6.
144. Nivard MJ, Pastink A, Vogel EW. Mutational spectra induced
under distinct excision repair conditions by the 3 methylating
agents N-methyl-N-nitrosourea, N-methyl-N'-nitro-N-nitro-
soguanidine and N-nitrosodimethylamine in postmeiotic male
germ cells of
Drosophila. Mutat Res
352: 97
e
against
murine
91.
166. Sanchez JJ, Monaghan G, Børsting C, Norbury G, Morling N,
Gaspar HB. Carrier frequency of a nonsense mutation in the
adenosine deaminase (ADA) gene implies a high incidence of
ADA-deficient severe combined immunodeficiency (SCID) in
Somalia and a single, common haplotype indicates common
ancestry.
Ann Hum Genet
2007;71:336
leukemia P388.
Cancer Res
1982;42:2587
e
115.
145. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW.
The role of base excision repair in the sensitivity and resistance to
temozolomide-mediated cell death.
Cancer Res
2005;65:6394
e
400.
146. Quiros S, Roos WP, Kaina B. Processing of O6-methylguanine
into DNA double-strand breaks requires two rounds of replica-
tion whereas apoptosis is also induced in subsequent cell cycles.
Cell Cycle
2010;9:168
47.
167. Carson DA, Kay J, Seegmiller JE. Lymphospecific toxicity in
adenosine deaminase deficiency and purine nucleoside phos-
phorylase deficiency: possible role of nucleoside kinase (s).
Proc
Natl Acad Sci, USA
1977;74:5677
e
e
81.
168. Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-
chlorodeoxyadenosine toward resting and proliferating human
lymphocytes.
Blood
1983;62:737
78.
147. Parker WB. Enzymology of purine and pyrimidine antimetabo-
lites used in the treatment of cancer.
Chem Rev
2009;109:2880
e
e
93.
148. Braess J, Jahns-Streubel G, Schoch C, et al. Proliferative activity of
leukaemic blasts and cytosine arabinoside pharmacodynamics
are associated with cytogenetically defined prognostic subgroups
in acute myeloid leukaemia.
Br J Haematol
2001;113:975
e
43.
169. Ross SR, McTavish D, Faulds D. Fludarabine: A review of its
pharmacological properties and therapeutic potential in malig-
nancy.
Drugs
1993;45:737
e
82.
149. Yamauchi T, Kawai Y, Ueda T. Inhibition of nucleotide excision
repair by fludarabine in normal lymphocytes in vitro, measured
by the alkaline single cell gel electrophoresis (Comet) assay.
Jpn J
Cancer Res
2002;93:567
59.
170. Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by
9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for
cytotoxicity.
J Biol Chem
1990;265:16617
e
e
25.
171. Parker WB, Bapat AR, Shen JX, Townsend AJ, Cheng YC. Inter-
action of 2-halogenated dATP analogs (F, Cl, Br) with human
DNA polymerases, DNA primase, ribonucleotide reductase.
Mol
Pharmacol
1988;34:485
e
73.
150. Robak T, Lech-Maranda E, Korycka A, Robak E. Purine nucleo-
side analogs as immunosuppressive and antineoplastic agents:
mechanism of action and clinical activity.
Curr Med Chem
2006;
13:3165
e
91.
172. Tseng WC, Derse D, Cheng YC, Brockman RW, Bennett Jr LL. In
vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluo-
roadenine and the biochemical actions of its triphosphate on
DNA polymerases and ribonucleotide reductase from HeLa cells.
Mol Pharmacol
1982;21:474
e
89.
151. Ho AD, Hensel M. Pentostatin and purine analogs for indolent
lymphoid malignancies.
Future Oncol
2006;2:169
e
83.
152. Sauter C, Lamanna N, Weiss MA. Pentostatin in chronic lympho-
cytic leukemia.
Expert Opin Drug Metab Toxicol
2008;4:1217
e
22.
153. Montgomery JA, Hewson K. Synthesis of potential anticancer
agents X: 2-fluoroadenosine.
J Am Chem Soc
1957;79:4559
7.
173. White EL, Shaddix SC, Brockman RW, Bennett Jr LL. Comparison
of the actions of 9-beta-D-arabinofuranosyl-2-fluoroadenine and
9-beta-D-arabinofuranosyladenine on target
e
e
63.
154. Skipper HE, Montgomery JA, Thomson JR, Schabel Jr FM.
Structure-activity relationships and cross-resistance observed on
evaluation of a series of purine analogs against experimental
neoplasms.
Cancer Res
1959;19:287
e
enzymes
from
4.
174. Gandhi V, Huang P, Chapman AJ, Chen F, Plunkett W. Incorpo-
ration of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-
triphosphates by DNA polymerase alpha: affinity, interaction,
consequences.
Clin Cancer Res
1997;3:1347
mouse tumor cells.
Cancer Res
1982;42:2260
e
308.
155. Montillo M, Ricci F, Tedeschi A. Role of fludarabine in hemato-
logical malignancies.
Expert Rev Anticancer Ther
2006;6:1141
e
61.
156. Mackey JR, Baldwin SA, Young JD, Cass CE. The role of nucle-
oside transport in anticancer drug resistance.
Drug Resistance
Updates
1998;1:310
55.
175. Parker WB, Cheng YC. Inhibition of DNA primase by nucleoside
triphosphates and their arabinofuranosyl analogs.
Mol Pharmacol
1987;31:146
e
e
24.
157. Molina-Arcas M, Casado FJ, Pastor-Anglada M. Nucleoside
transporter proteins.
Curr Vasc Pharmacol
2009;7:426
e
51.
176. Spriggs D, Robbins G, Mitchell T, Kufe D. Incorporation of 9-beta-
D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA
and DNA.
Biochem Pharmacol
1986;35:247
e
34.
158. Griffith DA, Jarvis SM. Nucleoside and nucleobase transport
systems ofmammaliancells.
BiochimBiophysActa
1996;1286:153
e
52.
177. Tomkinson AE, Lasko DD, Lindahl T. Biochemical properties of
mammalian DNA ligase I and the molecular defect in Bloom's
syndrome.
Prog Clin Biol Res
1990;340A:283
e
81.
159. Baldwin SA, Yao SY, Hyde RJ, et al. Functional characterization of
novel human and mouse equilibrative nucleoside transporters
(hENT3 and mENT3) located in intracellular membranes.
J Biol
Chem
2005;280:15880
e
94.
178. Yang SW, Huang P, Plunkett W, Becker FF, Chan JY. Dual mode of
inhibition of purified DNA ligase I from human cells by 9-beta-D-
arabinofuranosyl-2-fluoroadenine triphosphate.
J Biol Chem
1992;
267:2345
e
7.
160. Engel K, Wang J. Interaction of organic cations with a newly
identified plasma membrane monoamine transporter.
Mol Phar-
macol
2005;68:1397
e
9.
179. Gandhi V, Plunkett W. Modulation of arabinosylnucleoside
metabolism by arabinosylnucleotides in human leukemia cells.
Cancer Res
1988;48:329
e
407.
161. Weyand S, Shimamura T, Yajima S, et al. Structure and molecular
mechanism of a nucleobase-cation-symport-1 family transporter.
Science
2008;322:709
e
34.
180. Honma Y. A novel therapeutic strategy against monocytic
leukemia with deoxyadenosine analogs and adenosine deami-
nase inhibitors.
Leuk Lymphoma
2001;42:953
e
13.
162. GriffithDA, Jarvis SM. Expression of sodium-dependent nucleoside
transporters in.
Xenopus oocytes. Adv ExpMed Biol
1991;309A:431
e
4.
163. Gati WP, Paterson AR, Tyrrell DL, Cass CE, Moravek J,
Robins MJ. Nucleobase transporter-mediated permeation of 2',3'-
dideoxyguanosine in human erythrocytes and human T-lym-
phoblastoid CCRF-CEM cells.
J Biol Chem
1992;267:22272
62.
181. Leoni LM, Chao Q, Cottam HB, et al. Induction of an apoptotic
program in cell-free extracts by 2-chloro-2'-deoxyadenosine 5'-
triphosphate and cytochrome c.
Proc Natl Acad Sci, USA
1998;
95:9567
e
e
e
6.
e
71.
